⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VTGN News
Vistagen Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
VTGN
Vistagen to Present at Psych Congress 2026
globenewswire.com
VTGN
Chronic Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Domain | DelveInsight
globenewswire.com
TLRY
TAK
TNDM
NVS
BMY
PFE
INCY
JNJ
AZN
MRK
ABBV
CRSP
SCLX
RIGL
JAZZ
GILD
REGN
AMGN
BIIB
PTGX
EXAS
SNOW
SRPT
VRTX
BNTX
ALKS
RGEN
IMUX
ADPT
ATRC
CRNX
CYTK
DTIL
EXEL
FGEN
GALT
GNTX
GRFS
GSK
HRMY
IDXX
ILMN
INSM
IONS
IRWD
KODK
LAKE
LULU
LYFT
MAR
MDLZ
MELI
MIRM
MNKD
MRNA
MTCH
NBIX
NCLH
NEM
NTRA
NVCR
ODFL
OMER
ORGO
OTEX
PACB
PBYI
PCAR
PEGA
PERI
PETS
PLRX
PMVP
PPC
PRGS
PRTA
PSNL
PTN
PZZA
QGEN
QTRX
RARE
RCEL
RDHL
RLAY
RLGT
RMD
ROST
RRX
RYAAY
RYTM
SAN
SBAC
SBRA
SEIC
SIGA
SIRI
SITE
SLAB
SLGN
SMCI
SMMT
SNPS
SNY
SOFI
SONO
SPCE
SSYS
STNG
STRA
STRL
STX
SWKS
SYK
SYNA
TCOM
TDOC
TECK
TEVA
TFX
TGTX
TIGR
TRMB
TRVG
TTWO
TUSK
TXRH
ULTA
UMC
UNFI
UNH
URBN
UTHR
VEEV
VELO
VERU
VIVO
VKTX
VLRS
VNDA
VRSK
VSAT
VTGN
WDC
WEC
WERN
WGO
WIX
WMB
WST
WTW
WYNN
XOM
XPER
XPO
XRAY
YETI
YRD
YUM
ZBRA
ZLAB
ZYME
Form 8-K
sec.gov
VTGN
Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update
globenewswire.com
VTGN
Form 8-K
sec.gov
VTGN
Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
globenewswire.com
VTGN
Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
globenewswire.com
VTGN
Form 8-K
sec.gov
VTGN
SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN)
globenewswire.com
VTGN
SRXH